Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?

[1]  N. Meropol.  Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Bang,et al.  Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer , 2005, International journal of cancer.

[4]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Sunpaweravong,et al.  Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[6]  G. Pelosi,et al.  Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Kinay,et al.  Prognostic significance of EGF receptor expression in early glottic cancer. , 2004, Auris, nasus, larynx.

[9]  A. Jakobsen,et al.  Prognostic significance of p53, Her‐2, and EGFR overexpression in borderline and epithelial ovarian cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[10]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[11]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Swinson,et al.  Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer , 2004, British Journal of Cancer.

[13]  A. Gown,et al.  Testing for epidermal growth factor receptor in lung cancer: have we learned anything from HER-2 testing? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Figlin,et al.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[17]  M. Mori,et al.  Prediction of aggressive prostate cancer on biopsy using classification and regression tree analysis (CART). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  C. Elie,et al.  Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) , 2004, British Journal of Cancer.

[20]  P. Rehak,et al.  Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? , 2004, Journal of Clinical Pathology.

[21]  A. Santoro,et al.  Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.

[22]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[23]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[24]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[25]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression , 2004 .

[26]  C. Liedtke,et al.  Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma , 2004, Laboratory Investigation.

[27]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Andrle,et al.  Pharmacodiagnostic Value of the HER Family in Head and Neck Squamous Cell Carcinoma , 2004, ORL.

[29]  B. Goh,et al.  Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the Nasopharynx , 2004, The Laryngoscope.

[30]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  F. Schildberg,et al.  Reduced Survival of Rectal Cancer Patients With Increased Tumor Epidermal Growth Factor Receptor Levels , 2003, Diseases of the colon and rectum.

[33]  P. Bernard,et al.  Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma , 2003, Journal of surgical oncology.

[34]  M. Willingham,et al.  Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. , 2003, Molecular cancer therapeutics.

[35]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[36]  H. McLeod,et al.  Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.

[37]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[38]  B. Spaulding,et al.  Epidermal growth factor receptor expression and measurement in solid tumors. , 2002, Seminars in oncology.

[39]  C. Arteaga.  Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.

[40]  J. C. Lee,et al.  Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. , 2002, European journal of cancer.

[41]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[42]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[43]  A. Cheung,et al.  Expressions of c-erbB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. , 2001, Oncology reports.

[44]  J. Baselga.  The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.

[45]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  I. Spuẑić,et al.  Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease. , 1999, Journal of experimental & clinical cancer research : CR.

[48]  M. J. van de Vijver,et al.  Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Youngson,et al.  Comparison of different scoring systems for immunohistochemical staining. , 1999, Journal of clinical pathology.

[50]  T. Tzai,et al.  Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. , 1997, Anticancer research.

[51]  Y. Nio,et al.  Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. , 1997, Anticancer research.

[52]  M. Yano,et al.  Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand binding assay. , 1997, Oncology.

[53]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  J. Grandis,et al.  Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck , 1996, Cancer.

[55]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[56]  J. Kearsley,et al.  A comparison of epidermal growth factor receptor (EGFR) and c‐erbB‐2 oncogene expression in head and neck squamous cell carcinomas , 1991, Pathology.

[57]  D. Basketter,et al.  Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth. , 1983, Developmental biology.